Because pre-clinical data in mice had shown that best results were obtained with small tumor loads, ten patients who responded on chemotherapy were selected. We show for the first time the safety and feasibility of tumor lysate-pulsed dendritic cells as therapeutic adjuvants in mesothelioma patients and found distinct immune responses and antitumor responses in these patients.
INTRODUCTION
Malignant pleural mesothelioma (MM) is a fatal disease with median survival time from first signs of illness to death of < 12 months (1, 2). The incidence of mesothelioma is closely associated with exposure to airborne asbestos fibers (3) . Although the application of asbestos is prohibited in most developed countries, incidences of mesothelioma are increasing due to the incubation period of 20 to 50 years from initial exposure to asbestos to the onset of disease. For the Netherlands and most other European countries, deaths related to this disease are expected to continue rising until the year 2020 (4) . However, in numerous eastern and developing countries, asbestos is still used and as consequence incidences of mesothelioma worldwide will further rise (5). This anticipated increase in incidence of mesothelioma has spurred considerable interest to develop better treatments for mesothelioma.
Chemotherapy consisting of a combination of pemetrexed and cisplatin is regarded as standard of care for selected patients with mesothelioma (6) . The survival benefit is rather limited (~3 months) and new or additional treatment options like anti-angiogenesis drugs (bevacizumab), photodynamic therapy, gene therapy, and a variety of immunotherapy approaches are currently tested.
Immunotherapy is a promising approach in the treatment of cancer. It tries to harness the potency and specificity of the immune system to attack cancer cells, aiming for a non-toxic treatment with minor side-effects and a long-lasting immunological memory. One approach of immunotherapy uses dendritic cells (DC) to present tumor-associated antigens (TAA) and thereby generate tumor-specific immunity (7, 8) . DC are extremely potent antigen-presenting cells specialized for inducing activation and proliferation of CD8 + cytotoxic T lymphocytes (CTL) and helper CD4 + lymphocytes. Previously we investigated the effect of DC-based immunotherapy on the outgrowth of mesothelioma in a murine model (9) . As for mesothelioma the TAA are not known, we used tumor cell lysate as antigen source to pulse DC. We established that DC-based immunotherapy induced strong tumor-specific CTL responses leading to prolonged survival in mice (9) . The efficacy of immunotherapy was dependent on the tumor load. The most beneficial effects were established at early stages of tumor development. This is in agreement with our current knowledge of the effect of immunotherapy in other tumor types (10) .
On the basis of these preclinical animal studies, we have now completed a clinical trial in which autologous tumor lysate-pulsed DC were administered intradermally and intravenously in mesothelioma patients after cytoreductive therapy with chemotherapy. Patients received 50x10 6 mature DC pulsed with tumor lysate and KLH every two weeks for a total of three injections. The safety, feasibility and immunological effectiveness of this approach are reported.
METHODS
See the online supplement for more details regarding the preparation of the tumor lysate, flow cytometric analysis of clinical-grade DC, delayed-type hypersensitivity skin testing, immune response assessment against KLH, flow cytometric assays for interferon-gamma and granzyme B expression, and the cytotoxicity assays
Patient population
The study was approved by the institutional ethical committee of the Erasmus MC, A further description is detailed in the online supplement. From all participants, blood and serum samples were taken at regular intervals. Blood was tested for immunological responses, liver and renal functioning. In addition, serum samples were screened for the development of auto-immunity.
Preparation of tumor lysate
A detailed description of the preparation of the lysate can be found in the online supplement.
Single cell suspensions of tumor tissue (cases 2, 4, 5, and 10) and/or pleural effusions (cases 1, 3, 4, 6, 7, 8 and 9) were counted and resuspended at a concentration of 50x10 6 / ml in PBS.
Cells were lysed by six cycles of freezing in liquid nitrogen and thawing at room temperature followed by 100 Gy of irradiation. Large particles were removed by centrifugation (5 min, 200xg) , and supernatants were passed through a 0.45 μm filter. The resulting tumor lysates were stored in aliquots at -80°C until use.
Dendritic cell culture
We used a previously described method to generate clinical grade mature dendritic cells in conformity with GMP (Good Manufacturing Practice) guidelines (11) . Detailed information is outlined in the online supplement. In brief, concentrated leukocyte fractions were generated through peripheral blood leukapheresis. Peripheral blood mononuclear cells were then enriched using counter-flow centrifugal elutriation (Elutra) as described by Berger et al. (12) . 
Dendritic cell vaccination
Patients received three immunizations with mature DC loaded with autologous tumor lysate and KLH with a 2-week interval ( Figure 1 ). Each immunization, consisting of 50x10 6 cells, was intradermally (i.d.) and intravenously (i.v.) administered. Dosage was divided 1/3 i.d. in the forearm and 2/3 though i.v. route by mixing the components in 100 ml of normal saline drip. Constant monitoring was done till 4-h after the administration of vaccine therapy. The vaccine was routinely analyzed for DC purity and tested for infectious agents before administration to patients.
RESULTS
Ten patients who met the inclusion/exclusion criteria were enrolled after informed consent; all Routine sterility testing did not detect microbial contamination in any of the vaccines.
Toxicity
The vaccination regimen with loaded dendritic cells was overall well tolerated in all patients.
No dose adjustments or dose discontinuations were necessary. A local skin rash occurred at the site of the intradermal injection after the first vaccination in 8 of the 10 patients.
Subsequent vaccinations (second and third) gave a quicker and increased induration and erythema in all patients suggesting that some form of immunity was induced. In one patient (case 1), three millimeter skin punch biopsies were taken at day 2 and day 14 after the last injection of KLH and lysate-pulsed DC. In addition, adjacent normal, non-injected skin was also biopsied from the same individual. Microscopical examination of the immunohistochemical stainings showed a prominent thickening of the epidermis after 14 days Eight patients developed mild to severe flu-like symptoms after vaccination; particularly fever, muscle aches, chills and tiredness. Two patients showed these symptoms after the first vaccination; the others after the second and/or third injection. In 7 patients these symptoms normalized after one day. Most patients took paracetamol (acetaminophen) for 1 day as analgesic and antipyretic agent. One patient (case 6), in whom the reaction started after the first injection, the symptoms were more severe and paracetamol treatment was continued for 3
days. This patient did get chills after second and third vaccination. In none of the patients were observed in all patients until the final follow-up. There were no substantial changes in the results of routine blood tests.
Efficacy
The clinical responses were evaluated before and after immunotherapy by computed tomography (CT) scans and chest X-rays and analyzed according to the modified Response Evaluation Criteria in Solid Tumors (modified RECIST). Three patients showed partial responses after DC-immunotherapy, one stable disease and 6 patients had no response after vaccinations (Table 3 and 4) . The CT scans of a partial respons in patient 9 is shown in figure   3 . Two weeks after the DC vaccinations a second DTH skin test was performed. Cell lysates of autologous tumors, KLH, DC loaded with tumor lysate and KLH, DC loaded with tumor lysate, and an appropriate positive (tetanus toxoid) and negative (saline) control were injected intradermally and read 48 hours later. DTH skin testing revealed a response to dendritic cells loaded with tumor lysate and KLH, and to KLH alone in all patients (Table 3 ). Five patients responded on tumor lysate-loaded dendritic cells without KLH (Table 4 Chromium release assays were performed in 6 of the 10 patients from whom pleural fluid was obtained (cases 1, 3, 6, 7, 8, and 9, Table 4 ). Only these samples were suitable because viable single cell suspensions are needed for labeling with radioactive chromium for the cytotoxicity assay and therefore patients from whom tumor tissue was obtained (cases 2, 4, 5, and 10)
were excluded for this cytotoxicity assay. Almost no lysis of autologous tumor cells was observed before DC-treatment in these six patients. In four patients (cases 6, 7, 8, and 9) clear inductions of cytoxicity against autologous tumor cells were measurable. One patient (case 9) increased after every vaccination; for the three other patients (case 6, 7, and 8) three vaccinations were necessary to induce cytotoxicity ( Figure 5 ). Another assay that was used to assess the T cell capacity for cell lysis was the flow cytometric detection of CD3 + CD8 + T cells expressing granzyme B. Nine patients (1 remained at the same level) showed a significantly increased percentage of granzyme B + CD8 + T cells after vaccination (p=0.023; paired T test was used for comparing within-subject changes; Figure 6 ) and also the granzyme B expression per CD8 cell was increased in most patients (Table 4) .
DISCUSSION
To our knowledge, this is the first study assessing autologous monocyte-derived dendritic cells loaded with autologous tumor cell lysate in patients with mesothelioma. The primary objectives of this study were to determine the toxicity and feasibility of clinical grade DC and to investigate if mesothelioma might be susceptible to immunotherapy treatment. Ten patients fulfilled the in-and exclusion criteria and were enrolled in the study. Feasibility was defined as producing 3 doses of 50x10 6 autologous tumor-lysate loaded DC, each for intravenous (two thirds) and intradermal (one third) administration. In all apheresed subjects, sufficient cells were obtained from a single leukapheresis product, processed in vitro, injected (first vaccination), and cryopreserved for later administration (second and third vaccination). These results indicate that our method for producing large amounts of clinical-grade dendritic cells is feasible in patients with malignant mesothelioma.
The possibility to harness the potency and specificity of the immune system underlies the growing interest in cancer immunotherapy. One such approach uses the patient's own DC to present tumor-associated antigens and thereby generate tumor-specific immunity (7, 8) . We generated DC in large amounts ex-vivo, in the absence of the suppressing tumor milieu, and subsequently load them with a preparation of autologous tumor antigens. To prevent that antigens are presented by immature DC's, which might tolerize for tumour antigens and potentially enhance tumour growth (14, 15) , cells were matured using a standardized cytokine cocktail. Mature DC are injected both intraveneously (distribution to the liver, spleen and bone marrow) and intradermally where they then migrate to the regional lymphatics. In this way, they can maximally stimulate cytotoxic T cells, B-cells, T-cells, NK and NKT cells essential for tumor killing at different immunological organs.
We used a generally known and widely accepted method for the preparation and maturation of clinical grade dendritic cells (11, 12) . Autologous tumor lysate was used as the source of tumor antigen to load onto DC because in mesothelioma, specific tumor-associated antigens Table 3 ). 
Dendritic cell culture
We used a previously described method to generate clinical grade mature dendritic cells in conformity with GMP (Good Manufacturing Practice) guidelines (1). In brief, concentrated 120 to 150 ml leukocyte fractions were generated through a 4-h restricted peripheral blood leukapheresis, processing on average 9 L of blood (COBE Spectra Apheresis System, Gambro BCT, Zaventem, Belgium). Peripheral blood mononuclear cells were then enriched using counter-flow centrifugal elutriation (Elutra, Gambro BCT, Zaventem, Belgium) as described 
